Latest Gene therapy Stories
DUBLIN, May 28, 2015 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/szmlv3/gene_therapy) has announced the addition of Jain PharmaBiotech's
-Final 12-Month Results from Phase 2 STOP-HF Trial Presented in a Late-Breaker at European Society of Cardiology - Heart Failure 2015 and Published in European Heart Journal- CLEVELAND
Angiogenic Cardiovascular Gene Therapy: The Beauty of Biology and the Power of Regenerative Medicine SAN DIEGO, May 26, 2015 /PRNewswire/ -- Angionetics Inc., a majority-owned subsidiary
LONDON, May 19, 2015 /PRNewswire/ -- This report, The Market for Personalized Gene Therapy Treatments For Cancer provides an exhaustive review of the market potential for relatively new approach
Data from Disease Models of Hunter and Hurler Syndromes Demonstrate Proof of Concept for Sangamo's In Vivo Protein Replacement Platform RICHMOND, Calif., May 18, 2015 /PRNewswire/
SAN DIEGO, May 15, 2015 /PRNewswire/ -- Angionetics Inc., a majority-owned operating unit of Taxus Cardium Pharmaceuticals Group (Symbol: CRXM), today announced a presentation at the 18(th)
LONDON, May 13, 2015 /PRNewswire/ -- INTRODUCTIONSeveral disorders that arise inside the body are a result of either a direct genetic aberration or a dysfunctional/non-functional
SAN DIEGO, May 11, 2015 /PRNewswire/ -- Angionetics Inc., a majority-owned subsidiary of Taxus Cardium Pharmaceuticals Group Inc.
Accolade celebrates Netter’s dedication to bolstering local philanthropy and fighting cancer Stamford, CT (PRWEB) May 01, 2015 Barbara Netter — the
Companies to explore potential of Clearside's microinjector technology for use in delivering gene therapeutics to the retina and choroid through the suprachoroidal space PHILADELPHIA,
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.
More Images (1 images) »